We evaluated the activity of fluconazole and voriconazole against 83 Candida albicans isolates from patients with haematological malignancies, comparing the NCCLS microdilution method (M27-A) with a modified method with RPMI-2% glucose and MIC endpoint at 50% inhibition. Both drugs were highly active regardless of the year, the site of isolation of the strain and the test method employed. In several strains isolated during the last few years, trailing growth leading to difficulty in interpretation of the endpoint of the test has been observed for both drugs by the NCCLS method, but not by the modified method. In our experience, azole resistance of C. albicans is still not a clinical problem, however, the emerging phenomenon of the 'trailing effect' by the NCCLS method, even though resolvable by technical modifications, seems at least to indicate a reduction in the inhibitory activity of the azoles.
Introduction
The widespread use of fluconazole has been accompanied by a rising incidence of resistant Candida albicans isolates from late-stage AIDS patients. 1 In contrast, the true incidence and clinical impact of fluconazole resistance in cancer patients are controversial issues. 2, 3 The difficulties in the assessment of the degree of resistance to fluconazole and the other azoles are related to technical problems in the determination of their in vitro activity. The antifungal susceptibility method recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (the M27-A method) still has some limitations. 4 When testing azoles, a trailing endpoint, caused by a gradual decrease in growth rather than a distinct endpoint resulting from complete inhibition of growth, can lead to known susceptible strains appearing resistant. 5 In view of the above, modifications of the NCCLS method have been proposed. [6] [7] [8] [9] We evaluated the susceptibility to fluconazole and voriconazole of 83 C. albicans strains from patients with haematological malignancies, comparing the NCCLS reference microdilution method with a modified NCCLS microdilution method with RPMI-2% glucose, agitation and MIC endpoint at 50% inhibition.
Materials and methods

Patients
C. albicans isolates from patients with haematological malignancies undergoing remission induction chemotherapy or autologous bone marrow transplantation were enrolled in this study. Until 1990, most patients received antifungal prophylaxis with oral amphotericin B suspension (500 mg every 6 h). Between 1990 and 1993 fluconazole was the main agent used in prophylaxis. Based on the evidence that fluconazole, at a dose of 150 mg/day, was as effective as oral amphotericin B in the prevention of fungal infections in leukaemic patients, 10 administration of oral amphotericin B prophylaxis has become standard practice in our institution since 1994.
Candida sp. isolates
A total of 83 C. albicans isolates, from 80 patients, were used throughout this study. 
Antifungal agents
Fluconazole (2 mg/mL) and voriconazole (10 mg/mL) were prepared as stock solutions diluted in water. Both drugs were provided by Pfizer Central Research (Sandwich, UK).
NCCLS microdilution reference method
Antifungal agents were diluted with RPMI 1640 medium (Sigma Chemical Co., St Louis, MO) buffered to pH 7.0 with 0.165 M morpholinepropanesulphonic acid (MOPS) buffer (Sigma). Aliquots of 0.1 mL of the drug solutions were dispensed into each well of 96-well microtitre plates. The final concentrations of the antifungal agents ranged from 0.03 to 16 mg/L for voriconazole and 0.125 to 64 mg/L for fluconazole. C. albicans inocula, adjusted to a concentration of 1.0 ϫ 10 3 -5.0 ϫ 10 3 cfu/mL (twice the final inoculum) were added to each well of the microdilution plate. The MICs were determined after 48 h incubation at 35°C. The endpoint definition suggested by the NCCLS document M27-A 4 for the microdilution method is "a prominent reduction in turbidity". However, as well as for the macrodilution method, the MIC was defined more precisely as the lowest drug concentration that produced an 80% reduction of growth compared with that of the drug-free growth control.
Modified microdilution method with RPMI-2% glucose and MIC endpoint at 50% inhibition
Susceptibility testing was performed in RPMI 1640-glucose (final concentration of glucose 20 g/L) medium buffered to pH 7.0 with 0.165 M MOPS buffer. The final concentrations of the antifungal agents ranged from 0.0078 to 4 mg/L for voriconazole and 0.125 to 64 mg/L for fluconazole. The MICs were determined after 24 h incubation at 35°C. Microtitre plates were read after shaking for 3 min at 70 rpm. The MIC was defined as the lowest drug concentration that produced a 50% reduction of growth.
Results
The Table summarizes the isolates for fluconazole and 26% for voriconazole. When tested with the modified method, all the isolates regardless of the year of isolation were highly susceptible to fluconazole and voriconazole. The interpretation of the susceptibility data was easy, as distinct endpoints of growth inhibition were produced without trailing growth close to 50% inhibition.
The susceptibilities obtained by the NCCLS method for the 21 C. albicans strains isolated from blood are detailed in the Figure. Few patients had received fluconazole for prophylaxis or treatment and such exposure did not correlate with reduced susceptibility of subsequent isolates to the azole or difficulty in interpretation of trailing endpoints. Eleven of the 21 patients with candidaemia were treated with iv or oral fluconazole (400-800 mg/day). Only one patient died due to disseminated candidosis 2 days after the start of antifungal therapy. The other 10 patients responded to treatment, including the patient who developed a skin infection and septicaemia due to strain 148/1995 at the onset of his acute myeloid leukaemia and before hospital admission. Despite in vitro resistance of the microorganism to fluconazole as determined by the NCCLS reference method (demonstrated retrospectively), he was cured rapidly with fluconazole therapy (800 mg/day, iv).
Discussion
The so-called 'trailing effect' represents a crucial difficulty in determination of the MIC of azoles, which could lead to the interpretation of erroneously high MICs for susceptible strains. Therefore, modifications to the NCCLS method in terms of incubation time, buffer and glucose concentration, pH, inoculum size and endpoint determination criteria have been proposed. [6] [7] [8] [9] The use of RPMI-2% glucose and reading the endpoint at 80% reduction of growth, allowed for the rapid (24 h) and objective determination of the MICs compared with the standard NCCLS method. 7 In a multicentre study, agitation before reading and the use of 50% reduction of growth as the endpoint criterion improved intra-laboratory and inter-laboratory agreement and increased the frequency of interpretable MICs. 6 We have used a method that is based on RPMI-2% glucose, agitation and 50% growth inhibition as the endpoint criterion. By employing this method we have shown a slight reduction in the fluconazole and voriconazole MICs against most C. albicans isolates compared with those obtained by the standard NCCLS methodology. No trailing growth close to 50% inhibition was observed and results were therefore easy to interpret. Susceptibility of the C. albicans strains, as observed by the modified method, was confirmed in vivo by the efficacy of fluconazole therapy in 10 cases, including that of the bloodstream infection due to isolate 148/1995, which was resistant to fluconazole and voriconazole by the standard NCCLS method, but was susceptible to both drugs when the modified method was used. Our preliminary data support the evidence that modifications of the NCCLS method could reduce the bias of subjective interpretation and therefore lead to improvements in the reproducibility of antifungal susceptibility tests. However, our data seem to show that the 'trailing effect' is not only a technical problem related to the method employed. Unlike C. albicans strains isolated before or in the first years of the clinical use of fluconazole, several strains isolated in recent years were characterized by growth patterns that led to difficulty in interpretation of results.
The true clinical impact of fluconazole resistance in cancer patients is not known. In a survey conducted at a large cancer centre, 2 a 20% incidence of fluconazoleresistant C. albicans clinical isolates in recent years was associated with increasing fluconazole use, even if an individual association with previous use of the drug was not demonstrated. In contrast, in a recent study of yeast isolates causing bloodstream infections in neutropenic patients, fluconazole resistance was not identified in any of the C. albicans isolates tested. 3 In our experience in patients with haematological malignancies, resistance of C. albicans is not a clinical problem. It could be hypothesized that the selective use of fluconazole at our centre could have a role in the low incidence of fluconazole resistance. On the other hand, the increasing problem of the 'trailing effect' observed in susceptibility testing conducted by the NCCLS method, even though technically resolvable, seems at least to indicate a reduction in the 'in vitro' inhibitory activity of fluconazole and to a lesser extent voriconazole. This phenomenon does not appear to be related to the individual use of fluconazole but it could be hypothesized that the general pool of organisms is becoming more fluconazole tolerant.
